Biofourmis
https://www.biofourmis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biofourmis
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Digital Health Roundup: HLTH2022 Highlights, EU Updates, Diabetes Medtech Monthly
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent HLTH conference in Las Vegas. Reed Miller and Barnaby Pickering offer an overview of the highly competitive diabetes tech market. We also talk about digital health in Germany and Europe.
HLTH 2022 Roundup: Mirvie, Grail, Biofourmis, Komodo Health, Babson Diagnostics
This year’s annual HLTH meeting drew more than 9,000 people to Las Vegas from 13-16 November and hundreds of exhibitors. In this first part of a two-part roundup, Medtech Insight highlights interviews with C-suite executives at Mirvie, Grail, Biofourmis, Komodo Health and Babson Diagnostics.
Financing Quarterly Statistics, Q2 2022
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Company Information
- Industry
- Services
-
Medical Devices
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
-
Digital Health
- Disease Management
- Artificial Intelligence
- Other Names / Subsidiaries
-
- N/A
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice